|LETTER TO EDITOR
|Year : 2015 | Volume
| Issue : 1 | Page : 61-62
Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient
J Joseph, A Vimala
Department of Nephrology, SMCSI Medical College, Karakonam, Trivandrum, Kerala, India
|Date of Web Publication||12-Jan-2015|
Department of Nephrology, SMCSI Medical College, Karakonam, Trivandrum, Kerala
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Joseph J, Vimala A. Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient. Indian J Nephrol 2015;25:61-2
A 49-year-old diabetic male on maintenance hemodialysis for 8 months presented with complaints of pain and swelling in the left ear. Investigation revealed hemoglobin of 7.4 g/dl; leukocyte count of 28,400 cells/μL; differential count polymorphs, 86% and lymphocytes, 9%. He was treated with ear packs and oral ciprofloxacin. However, the pain and swelling worsened. Computerized tomography scan of skull showed extensive damage of middle ear and ear ossicles [Figure 1] with skull bone erosions [Figure 2] suggestive of malignant otitis externa. Ceftazidime 1 g twice daily intravenously was added. Considering the potential life- threatening nature of illness, we gave a higher than his renal adjusted dose for ceftazidime. After 2 days of starting ceftazidime, the patient developed myoclonic movements of upper limb and was confused. Since patient was on ciprofloxacin for more than 2 weeks, it was stopped considering it might be contributing to the patient's condition. Magnetic resonance imaging of brain was normal and there was no evidence of extension of infection to brain. He developed generalized myoclonic movements with alteration in sensorium by 4 th day of staring ceftazidime, requiring intensive care support. His myoclonus and encephalopathy was not showing any change in post dialysis period and was present during sleep also. Since his condition was worsening and no other identifiable causative factors were evident in clinical examination, ceftazidime was stopped. Two days later, his movements were reduced and sensorium improved. By 5 th day the patient was fully conscious and myoclonic movements resolved completely. However, he continued to have his ear symptoms and underwent modified radical mastoidectomy. Histology showed granulation tissues. He was continued on ciprofloxacin and was discharged with advice to continue antibiotics for total duration of 3 months. There was no recurrence of myoclonus.
Myoclonus can occur as a side effect of multiple medications.  The mechanisms responsible for drug-induced myoclonus is not well understood.  Ceftazidime, is a third-generation cephalosporin widely used for the empiric treatment of infection in dialysis patients because of its broad antibacterial spectrum. But cautious adjustment in dosage is imperative for patients with renal insufficiency.  The mechanism of neurotoxicity and convulsions caused by cephalosporins involves the inhibition of γ-aminobutyric acid (GABA) binding to GABA receptors.  Impairment in active transport of cephalosporins from cerebrospinal fluid to blood due to competitive inhibition by accumulated toxic organic acids in patients with renal failure may account for the susceptibility to neurotoxicity.  Drug-induced myoclonus usually resolves after withdrawal of the offending drug. In this patient, the temporal association of the development of myoclonus after starting ceftazidime, and resolution following the discontinuation strongly suggests a causal relationship.
|Figure 1: Computed tomography scan skull showing extensive damage of left middle ear and ossicles|
Click here to view
|Figure 2: Computed tomography skull coronal bone window showing skull base erosion|
Click here to view
Due to the uncommon nature of the movement disorders induced by ceftazidime, which is commonly used in dialysis patients closer monitoring is advisable.
| References|| |
Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol 2002;89:49-76.
Jiménez-Jiménez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: Frequency, mechanisms and management. CNS Drugs 2004;18:93-104.
Slaker RA, Danielson B. Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction. Pharmacotherapy 1991;11:351-2.
Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F, et al.
Evidence for the involvement of GABA (A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003;45:304-14.
Richet G, Lopez de Novales E, Verroust P. Drug intoxication and neurological episodes in chronic renal failure. Br Med J 1970;2:394-5.
[Figure 1], [Figure 2]